Hospitalization cost estimates of respiratory syncytial virus and influenza infections in adults in Spain, 2016-2019.

Vaccine Pub Date : 2025-02-06 Epub Date: 2024-12-27 DOI:10.1016/j.vaccine.2024.126683
M Haeberer, A López-Ibáñez de Aldecoa, S Seabroke, J L Ramirez Agudelo, L Mora, L Sarabia, P Peerawaranun, E Meroc, Z Aponte-Torres, A W Law, R Sato
{"title":"Hospitalization cost estimates of respiratory syncytial virus and influenza infections in adults in Spain, 2016-2019.","authors":"M Haeberer, A López-Ibáñez de Aldecoa, S Seabroke, J L Ramirez Agudelo, L Mora, L Sarabia, P Peerawaranun, E Meroc, Z Aponte-Torres, A W Law, R Sato","doi":"10.1016/j.vaccine.2024.126683","DOIUrl":null,"url":null,"abstract":"<p><p>Respiratory syncytial virus (RSV) is increasingly a recognized cause of severe respiratory infection among adults. This retrospective observational study compared the costs of RSV and influenza hospitalizations in adults aged ≥18 years admitted to the Spanish National Healthcare System between 2016 and 2019. Mean costs per hospitalization episode were compared using a multivariable log-gamma generalized linear model adjusted by age, risk group and calendar year. Total annual hospitalization costs were estimated from population incidence rates (for RSV we used model-based rates reported in a published study due to the substantial under-ascertainment of cases) and the mean cost per episode. ICD-10 codes identified a total of 11,662 adults hospitalized with RSV and 79,319 with influenza. The mean length of stay was longer for RSV than for influenza in low-risk patients aged 60-79 years, moderate-risk patients (those with chronic medical conditions) aged ≥50 years and in high-risk (those with immunocompromising conditions) patients aged <80 years. There were no differences in intensive care unit (ICU) admission (except for higher admission in high-risk RSV patients aged 70-79 years), ICU stay or in-hospital case fatality rate. Mean costs per hospitalization episode were also similar: RSV €3870 (95 % CI 3773-3942) vs influenza €3888 (95 % CI 3836-3931). Total annual costs for RSV-attributable hospitalizations were estimated at M€194, twice than that of influenza (M€83). Annual costs increased by 11 % over the study period for RSV and by 47 % for influenza. In 2019, adults aged ≥60 years and ≥ 70 years contributed 91 % and 82 %, respectively, of the total RSV-attributable hospitalization costs in adults. RSV has a significant economic burden to the Spanish National Healthcare System, likely greater than influenza. Efficacious RSV vaccines and antivirals have the potential for high public health impact.</p>","PeriodicalId":94264,"journal":{"name":"Vaccine","volume":"46 ","pages":"126683"},"PeriodicalIF":0.0000,"publicationDate":"2025-02-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Vaccine","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1016/j.vaccine.2024.126683","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/12/27 0:00:00","PubModel":"Epub","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Respiratory syncytial virus (RSV) is increasingly a recognized cause of severe respiratory infection among adults. This retrospective observational study compared the costs of RSV and influenza hospitalizations in adults aged ≥18 years admitted to the Spanish National Healthcare System between 2016 and 2019. Mean costs per hospitalization episode were compared using a multivariable log-gamma generalized linear model adjusted by age, risk group and calendar year. Total annual hospitalization costs were estimated from population incidence rates (for RSV we used model-based rates reported in a published study due to the substantial under-ascertainment of cases) and the mean cost per episode. ICD-10 codes identified a total of 11,662 adults hospitalized with RSV and 79,319 with influenza. The mean length of stay was longer for RSV than for influenza in low-risk patients aged 60-79 years, moderate-risk patients (those with chronic medical conditions) aged ≥50 years and in high-risk (those with immunocompromising conditions) patients aged <80 years. There were no differences in intensive care unit (ICU) admission (except for higher admission in high-risk RSV patients aged 70-79 years), ICU stay or in-hospital case fatality rate. Mean costs per hospitalization episode were also similar: RSV €3870 (95 % CI 3773-3942) vs influenza €3888 (95 % CI 3836-3931). Total annual costs for RSV-attributable hospitalizations were estimated at M€194, twice than that of influenza (M€83). Annual costs increased by 11 % over the study period for RSV and by 47 % for influenza. In 2019, adults aged ≥60 years and ≥ 70 years contributed 91 % and 82 %, respectively, of the total RSV-attributable hospitalization costs in adults. RSV has a significant economic burden to the Spanish National Healthcare System, likely greater than influenza. Efficacious RSV vaccines and antivirals have the potential for high public health impact.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
2016-2019年西班牙成人呼吸道合胞病毒和流感感染住院费用估算
呼吸道合胞病毒(RSV)越来越被认为是成年人严重呼吸道感染的原因。这项回顾性观察性研究比较了2016年至2019年西班牙国家医疗保健系统收治的年龄≥18岁成人RSV和流感住院治疗的成本。使用多变量log-gamma广义线性模型对每次住院发作的平均费用进行比较,该模型经年龄、风险组和历年校正。每年总住院费用是根据人群发病率(对于呼吸道合胞病毒,我们使用了一项已发表的研究中报告的基于模型的发病率,因为病例的确定程度严重不足)和每次发作的平均费用来估计的。ICD-10代码共确定了11,662名因RSV住院的成年人和79,319名因流感住院的成年人。年龄在60-79岁的低危患者、年龄≥50岁的中危患者(有慢性疾病的患者)和年龄在50岁以上的高危患者(有免疫功能低下的患者)中,RSV患者的平均住院时间长于流感患者
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
A neuraminidase-based inactivated influenza virus vaccine significantly reduced virus replication and pathology following homologous challenge in swine. Vaccine safety surveillance in South Africa through COVID-19: A journey to systems strengthening. Comprehensive humoral and cellular immune responses to COVID-19 vaccination in adults with cancer. Predictors of HPV vaccination coverage among adolescents in Tennessee during the COVID-19 pandemic: A cross-sectional study. Pseudovirus nanoparticles targeting the receptor binding HA1 domains of influenza viruses elicited high HA1-specific antibody responses and protected mice against mortality caused by influenza virus challenges.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1